<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00516178</url>
  </required_header>
  <id_info>
    <org_study_id>FN-3200BO-102064</org_study_id>
    <nct_id>NCT00516178</nct_id>
  </id_info>
  <brief_title>Intravenous Fish Oil in Critically Ill Cardiac Patients</brief_title>
  <acronym>FO-cardiac</acronym>
  <official_title>Effects of Intravenous n-3 Polyunsaturated Fatty Acid Administration in Critically Ill Cardiac Surgery and Myocardial Infarction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A large body of evidence has accumulated showing that n-3 PUFAs exert extensive cardiac
      effects. The development of commercial solutions of FO opens perspectives for therapeutic
      applications in patients with acute cardiac conditions.the 3 following hypotheses will be
      addressed in patients requiring cardiac surgery under cardiopulmonary bypass or after
      myocardial infarction:perioperative /post-PTCA intravenous fish oil modifies the composition
      of membrane phospholipids in platelets and cardiac cells, blunts the physiological response
      to cardiac surgery/myocardial infarction, and reduces the incidence of arrhythmias, and
      reduces the occurrence of systolic dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A. Randomized trial in 40 cardiac surgery patients Early rapid infusion of fish oil (3 times
      in 24 hours) in cardiac surgery patients.

      B. Randomized trial 20 myocardial infarction patients (abandonned) Continuous infusion of the
      same dose over 24hrs in the myocardial infarction patients

      Additional trial in healthy volunteers (investigating physiological changes after cardiac
      study):

      -Open trial in 8 healthy lean volunteers to investigate the impact of the same 0.6 g/kg FO
      dose IV (Week 1: 3hrs), and then orally on week 2, on platelet n-3 PUFA incorporation,
      platelet function, heart rate and peak flow response to stress test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incorporation of n-3 PUFA into platelet cell membrane and myocardial tissue</measure>
    <time_frame>48 hours</time_frame>
    <description>The primary outcome is the determination of magnitude of the incorporation and the time required for incorporation of omega-3 fatty acid cell membrane composition after short intravenous infusions was unknown until the present study (HPLC determination of fatty acid membrane composition in all patients)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammatory and metabolic response</measure>
    <time_frame>From operation to ICU discharge (maximum 28 days)</time_frame>
    <description>cytokine determination, CRP, glucose control (blood levels and insulin requirements) in all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global clinical outcome</measure>
    <time_frame>From operation to hospital discharge (maximum 28 days)</time_frame>
    <description>length of mechanical ventilation, length of ICU and hospital stay in all patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial recovery after surgery</measure>
    <time_frame>From operation to hospital discharge (maximum 28 days)</time_frame>
    <description>Holter monitoring during cardiac surgery or for 72 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (No lipid emulsion)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil emulsion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 infusions of 0.2 g/kg omega-3 PUFA within 24 hours in cardiac surgery (continuous infusion post-PTCA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fish oil emulsion</intervention_name>
    <description>0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA</description>
    <arm_group_label>Fish oil emulsion</arm_group_label>
    <other_name>Omegaven,Fresenius Kabi AG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>3 infusions, perioperative or post-PTCA</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Coronary artery disease requiring elective surgical repair under cardiopulmonary
             bypass

          -  Acute myocardial infarction requiring ICU management

        Exclusion Criteria:

          -  Absence of consent

          -  Ventricular ejection fraction &lt; 35%

          -  Beating heart surgery or emergency surgery

          -  Hypercholesterolemia &gt; 5 mmol/l

          -  Thrombolysis

          -  Chronic steroid therapy

          -  Acute or chronic renal failure prior to surgery (plasma creatinine &gt; 150 umol/l)

          -  Chronic coagulation disorder

          -  Premenopausal female

          -  Consumption of more than 3 times fish per week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mette M Berger, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Serviceof Adult Intensive Care, CHUV</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHUV</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service of Adult Intensive Care - CHUV</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Berger MM, Delodder F, Liaudet L, Tozzi P, Schlaepfer J, Chiolero RL, Tappy L. Three short perioperative infusions of n-3 PUFAs reduce systemic inflammation induced by cardiopulmonary bypass surgery: a randomized controlled trial. Am J Clin Nutr. 2013 Feb;97(2):246-54. doi: 10.3945/ajcn.112.046573. Epub 2012 Dec 26.</citation>
    <PMID>23269816</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2007</study_first_posted>
  <last_update_submitted>February 14, 2016</last_update_submitted>
  <last_update_submitted_qc>February 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Mette M Berger</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>Fish oil supplement</keyword>
  <keyword>n-3 PUFA</keyword>
  <keyword>Cardiac function</keyword>
  <keyword>Membrane incorporation</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Clinical outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

